What does today’s Supreme Court decision striking down tariffs mean for the pharmaceutical industry?

https://www.managedhealthcareexecutive.com/view/what-does-today-s-supreme-court-decision-striking-down-tariffs-mean-for-the-pharmaceutical-industry-?utm_campaign=KHN%3A%20First%20Edition&utm_medium=email&_hsenc=p2ANqtz-8i7_yrYxYjAntDkSc4u_yZkMzM0s_kCmFL5zNFTnLjUlIQZJr-luwh8KoRfMTDK_uVtQklBLyvZI5u1-8xfCkEqDm1Rw&_hsmi=405016981&utm_content=405016981&utm_source=hs_email Managed Healthcare Executive: What Does The Supreme Court Decision Striking Down Tariffs Mean For The Pharmaceutical Industry? The Trump administration has other legal avenues to impose tariffs on pharmaceuticals despite the Supreme Court decision striking down many of the administration’s current tariffs. In a 6-3 decision, the court ruled that President Donald Trump did not have the authority to impose tariffs under a 1977 law, the International Emergency Economic Powers Act. But at a White House press conference, Trump said there were numerous other statutes and authorities that give the president the power to impose tariffs. He cited Sections 122 and 301 of the Trade Act of 1974; Section 232 of the Trade Expansion Act of 1962; and Section 338 of the Tariff Act of 1930, commonly referred to as the Smoot-Hawley Tariff Act. He also announced that he would impose a broad tariff of 10% under Section 122 of the Trade Act of 1974, effectively replacing tariffs he imposed under the international emergency law that the court struck down. (Wehrwein, 2/21)